Immunogenicity of the pentavalent rotavirus vaccine in African infants

Vaccine

Volumn 30, Issue SUPPL. 1, 2012, Pages

  Armah, George E ^a   Breiman, Robert F ^b   Tapia, Milagritos D ^c,d   Dallas, Michael J ^e   Neuzil, Kathleen M ^f   Binka, Fred N ^g   Sow, Samba O ^c,d   Ojwando, Joel ^b,h   Ciarlet, Max ^e,i   Steele, A Duncan ^f  

^a University of Ghana   (Ghana)

^b Centers for Disease Control and Prevention Kenya   (Kenya)

^c Centre pour le Developpement des Vaccins   (Mali)

^d UNIVERSITY OF MARYLAND   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

^f PATH   (United States)

^g UNIVERSITY OF GHANA   (Ghana)

^h KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

ⁱ NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

Author keywords

Africa; Immunogenicity; Pentavalent rotavirus vaccine; Rotavirus

Indexed keywords

IMMUNOGLOBULIN A; NEUTRALIZING ANTIBODY; PLACEBO; ROTAVIRUS VACCINE;

ARTICLE; BREAST FEEDING; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FOLLOW UP; GHANA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; KENYA; MALI; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ROTAVIRUS; SEROTYPE; VIRAL GASTROENTERITIS;

ADMINISTRATION, ORAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; FEMALE; GASTROENTERITIS; GHANA; HUMANS; IMMUNOGLOBULIN A; INFANT; KENYA; MALE; MALI; PLACEBOS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINATION; VACCINES, ATTENUATED;

EID: 84860012609     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.10.006     Document Type: Article

References (30)

1. Black R.E., Cousens S., Johnson H.L., Lawn J.E., Rudan I., Bassani D.G., et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 2010, 375(9730):1969-1987.
2. Tate J.E., Burton A.H., Boschi-Pinto C., Steele A.D., Duque J., Parashar U.D., et al. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12(2):131-141.
3. Glass R.I., Bresee J.S., Turcios R., Fischer T.K., Parashar U.D., Steele A.D. Rotavirus vaccines: targeting the developing world. J Infect Dis 2005, 192(Suppl. 1):S160-S166.
4. Cunliffe N.A., Kilgore P.E., Bresee J.S., Steele A.D., Luo N., Hart C.A., et al. Epidemiology of rotavirus diarrhoea in Africa: a review to assess the need for rotavirus immunization. Bull World Health Organ 1998, 76(5):525-537.
5. Ciarlet M., Schödel F. The path to rotavirus vaccine development and the clinical data supporting safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, Rotateq. Vaccine 2009, 27(Suppl. 6):G72-G81.
6. Fischer T.K., Valentiner-Branth P., Steinsland H., Perch M., Santos G., Aaby P., et al. Protective immunity after natural rotavirus infection: a community cohort study of newborn children in Guinea-Bissau, West Africa. J Infect Dis 2002, 186(5):593-597.
7. Velázquez F.R., Matson D.O., Guerrero M.L., Shults J., Calva J.J., Morrow A.L., et al. Serum antibody as a marker of protection against natural rotavirus infection and disease. J Infect Dis 2000, 182(6):1602-1609.
8. Ward R.L., Clark H.F., Offit P.A. Influence of potential protective mechanisms on the development of live rotavirus vaccines. J Infect Dis 2010, 202(Suppl.):S72-S79.
9. Jiang B., Gentsch J.R., Glass R.I. The role of serum antibodies in the protection against rotavirus disease: an overview. Clin Infect Dis 2002, 34(10):1351-1361.
10. Linhares A.C., Velázquez F.R., Pérez-Schael I., Saez-Llorens X., Abate H., Espinoza F., et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 2008, 371(April (9619)):1181-1189.
11. Vesikari T., Matson D.O., Dennehy P., Van Damme P., Santosham M., Rodriguez Z., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354(1):23-33.
12. Ruiz-Palacios G.M., Pérez-Schael I., Velázquez F.R., Abate H., Breur T., Clemens S.C., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354(1):11-22.
13. Vesikari T., Karvonen A., Ferrante S.A., Ciarlet M. Efficacy of the pentavalent rotavirus vaccine, RotaTeq®, in Finnish infants up to 3 years of age: the Finnish Extension Study. Eur J Pediatr 2010, 169(11):1379-1386.
14. WHO Conclusions and recommendations from the Immunization Strategic Advisory Group. Wkly Epidemiol Rec 2006, 81(1):2-11.
15. Armah G.E., Sow S.O., Breiman R.F., Dallas M.J., Tapia M.D., Feikin D.R., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376(9741):606-614.
16. Laserson K., Nyakundi D., Feikin D.R., Nyambane G., Cook E., Oyieko J., et al. Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq®, in Kenya, including among HIV-infected and HIV-exposed infants. Vaccine 2012, 30(Suppl. 1):A61-A70.
17. Knowlton D.R., Spector D.M., Ward R.L. Development of an improved method for measuring neutralizing antibody to rotavirus. J Virol Methods 1991, 33:127-134.
18. Ciarlet M., Sani-Grosso R., Yuan G., Liu G.F., Heaton P.M., Gottesdiener K.M., et al. Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine. Pediatr Infect Dis J 2008, 27(10):874-880.
19. Ciarlet M., He S., Lai S., Petrecz M., Yuan G., Liu G.F., et al. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity. Pediatr Infect Dis J 2009, 28(3):177-181.
20. Kim D.S., Lee T.J., Kang J.H., Kim J.H., Lee J.H., Ma S.H., et al. Immunogenicity and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy infants in Korea. Pediatr Infect Dis J 2008, 27(2):177-178.
21. Vesikari T., Karvonen A., Ferrante S.A., Kuter B.J., Ciarlet M. Sustained efficacy of the pentavalent rotavirus vaccine: RV5, up to 3.1 years following the last dose of vaccine. Pediatr Infect Dis J 2010, 29(10):957-963.
22. Chang C.C., Chang M.H., Lin T.Y., Lee H.C., Hsieh W.S., Lee P.I. Experience of pentavalent human-bovine reassortant rotavirus vaccine among healthy infants in Taiwan. J Formos Med Assoc 2009, 108(4):280-285.
23. Rodríguez Z.M., Goveia M.G., Stek J.E., Dallas M.J., Boslego J.W., DiNubile M.J., et al. Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States. Pediatr Infect Dis J 2007, 26(3):221-227.
24. Velázquez F.R., Matson D.O., Calva J.J., Guerrero L., Morrow A.L., Carter-Campbell S., et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 1996, 335(14):1022-1028.
25. Patel M., Shane A.L., Parashar U.D., Jiang B., Gentsch J.R., Glass R.I. Oral rotavirus vaccines: how well will they work where they are needed most?. J Infect Dis 2009, 200(Suppl. 1):S39-S48.
26. Zaman K., Sack D.A., Yunus M., Arifeen S.E., Podder G., Azim T., et al. Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. Vaccine 2009, 27(9):1333-1339.
27. Steele A.D., De Vos B., Tumbo J., Reynders J., Scholtz F., Bos P., et al. Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. Vaccine 2010, 28(39):6542-6548.
28. Tregnaghi M.W., Abate H.J., Valencia A., Lopez P., Da Silveira T.R., Rivera L., et al. Human rotavirus vaccine is highly efficacious when coadministered with routine expanded program of immunization vaccines including oral poliovirus vaccine in Latin America. Pediatr Infect Dis J 2011, 30(6):e103-e108.
29. Markwick A.J., Rennels M.B., Zito E.T., Wade M., Mack M.E. Oral tetravalent rotavirus vaccine can be administered with oral poliovirus vaccine and a combined diphtheria: tetanus, pertussis and Haemophilis influenza type b vaccine. Pediatr Infect Dis J 1998, 17(10):913-918. US Rhesus Rotavirus vaccine Study Group.
30. Moon S.S., Wang Y., Shane A.L., Nguyen T., Ray P., Dennehy P., et al. Inhibitory effect of breast milk on infectivity of live oral rotavirus vaccines. Pediatr Infect Dis J 2010, 29:919-923.